Observational studyBMC pediatrics2025
Assessment of quality of life, treatment practices, and associated factors among children of atopic dermatitis patients at all Africa leprosy, TB and rehabilitation training center (A.L.E.R.T): a prospective observational study.
Observational study in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Atopic dermatitis and its associated factors in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtopic dermatitis (AD) is the most common chronic skin disease in children. It adversely affects child's physical health, daily functioning, and overall quality of life (QoL), impacting not only the child but also their families. There is a paucity of data in Ethiopia about treatment practices and QoL among children with AD. Thus, this study aimed to assess QoL, treatment practice, AD symptom control statues and associated factors for QoL among children with AD at ALERT dermatovenerology unit, Addis Ababa, Ethiopia.
methodProspective observational study was employed on 403 patients. Structured questionnaire and Child Dermatology Life Quality Index (CDLQI) tool were used to collect the data. Descriptive statistics and multivariable logistic regression model were used to analyze the data.
resultsThe mean (± SD) age of participants was 8.04 (± 3.40) years. Topically applied readymade medicine, antihistamine and emollient were given for (55.6%, n = 224), (24.3%, n = 98) and (75.8%, n = 305) participants, respectively. The mean (± SD) QoL was 8.42(± 3.57) indicating moderate effect. Domain of itching, dressing and sleeping was the utmost affected QoL. Three-fourths (76.9%, n = 310) of patients had their AD symptoms controlled. Caregivers who were government employees [AOR = 4.9, 95% CI: 1.22, 19.71, P = 0.02], daily labourer caregivers [AOR = 7.3, 95% CI: 1.15, 45.7, P = 0.03] and, those with moderate AD [AOR = 2.8, 95 % CI: 1.59, 4.96, P = <0.001] were significantly associated with QoL, as well as caregivers with very low (≤ 860) [AOR = 0.09, 95% CI: 0.01, 0.68, P = 0.02], low (861-1500) monthly income [AOR = 0.20, 95% CI: 0.05, 0.90, P = 0.03].
conclusionPatients with AD had a moderate QoL based on their CDLQL score. Three-fourths of the study participants who experienced AD-related symptoms had them controlled after 4 weeks of treatment. Among the CDLQI domains, itching and scratching, dressing problems and sleeping problems were the most affected. Caregiver employment status, monthly income, moderate type of AD and facial involvement were significantly associated with QoL outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.